skip to main content
Idioma:
Tipo de recurso Mostra resultados com: Mostra resultados com: Índice

Cancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment

Ganguly, Debolina ; Chandra, Raghav ; Karalis, John ; Teke, Martha ; Aguilera, Todd ; Maddipati, Ravikanth ; Wachsmann, Megan B. ; Ghersi, Dario ; Siravegna, Giulia ; Zeh, Herbert J. ; Brekken, Rolf ; Ting, David T. ; Ligorio, Matteo

Cancers, 2020-09, Vol.12 (9), p.2652 [Periódico revisado por pares]

MDPI AG

Texto completo disponível

Citações Citado por
  • Título:
    Cancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment
  • Autor: Ganguly, Debolina ; Chandra, Raghav ; Karalis, John ; Teke, Martha ; Aguilera, Todd ; Maddipati, Ravikanth ; Wachsmann, Megan B. ; Ghersi, Dario ; Siravegna, Giulia ; Zeh, Herbert J. ; Brekken, Rolf ; Ting, David T. ; Ligorio, Matteo
  • Assuntos: cancer-associated fibroblasts ; chemoresistance ; Fibroblasts ; hallmarks of cancer ; Health aspects ; heterogeneity ; immunomodulation ; Review ; tumor microenvironment ; Tumors
  • É parte de: Cancers, 2020-09, Vol.12 (9), p.2652
  • Notas: ObjectType-Article-2
    SourceType-Scholarly Journals-1
    ObjectType-Feature-3
    content type line 23
    ObjectType-Review-1
    These authors contributed equally to this work.
  • Descrição: Cancer-associated fibroblasts (CAFs) are indispensable architects of the tumor microenvironment. They perform the essential functions of extracellular matrix deposition, stromal remodeling, tumor vasculature modulation, modification of tumor metabolism, and participation in crosstalk between cancer and immune cells. In this review, we discuss our current understanding of the principal differences between normal fibroblasts and CAFs, the origin of CAFs, their functions, and ultimately, highlight the intimate connection of CAFs to virtually all of the hallmarks of cancer. We address the remarkable degree of functional diversity and phenotypic plasticity displayed by CAFs and strive to stratify CAF biology among different tumor types into practical functional groups. Finally, we summarize the status of recent and ongoing trials of CAF-directed therapies and contend that the paucity of trials resulting in Food and Drug Administration (FDA) approvals thus far is a consequence of the failure to identify targets exclusive of pro-tumorigenic CAF phenotypes that are mechanistically linked to specific CAF functions. We believe that the development of a unified CAF nomenclature, the standardization of functional assays to assess the loss-of-function of CAF properties, and the establishment of rigorous definitions of CAF subpopulations and their mechanistic functions in cancer progression will be crucial to fully realize the promise of CAF-targeted therapies.
  • Editor: MDPI AG
  • Idioma: Inglês
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.